You are here

Magazine

0

New publication for Utipro® Plus / Utipro® Plus AF

Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of a meta-analysis in which the benefit of the combination of a mucoprotectant (xyloglucan or an equivalent substance), hibiscus and propolis in the management of uncomplicated urinary tract infections has been evaluated. Among different available publications, three of them were integrated into the final analysis leading the authors to interesting conclusions: “In the era of antibiotic resistance, an antibiotic-sparing approach presents an interesting alternative treatment of uncomplicated cystitis in women…“ and “A medical device containing xyloglucan, hibiscus and propolis is superior to comparator regimens in terms of clinical effectiveness in adult women with microbiologically confirmed or clinical suspicion of uncomplicated cystitis and is associated with a high patient compliance”, thus reinforcing the usefulness of Utipro® Plus/Utipro® Plus AF in acute and recurrent uncomplicated UTIs.

Read more

Launch of TASECTAN® AF in Finland and Sweden

Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets. TASECTAN® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children. TASECTAN® AF is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL). For more information about our products click here: http://noventure.com/products

Read more

UTIPRO® PLUS Launched in Denmark

We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Denmark. The product is commercialized under the brand UrinCUR / Utipro plus and it is already present in Sweden, Norway and Finland, distributed as well by our partner RFSU. Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.

Read more

Let's meet in..

2022, Feb 01

EWMA

Read more

2022, Mar 07

28th International Conference on Clinical Nutrition 2022

Read more

2022, Mar 18

EAU22

Read more